HPV 16+ Cancer Pipeline Analysis: Insights into Emerging Therapies, Key Companies, Clinical Trials and Future Pipeline Outlook | DelveInsight

Loading...
Loading...

Los Angeles, USA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HPV 16+ Cancer Pipeline Analysis: Insights into Emerging Therapies, Key Companies, Clinical Trials and Future Pipeline Outlook | DelveInsight 

HPV 16+ Cancer Pipeline is in its nascent stage and is developing with a more targeted therapeutic approach combined with other approved treatments.

DelveInsight's HPV 16+ Cancer Pipeline Insights' report offers comprehensive coverage of the emerging HPV 16+ Cancer therapeutics outlook in different stages of clinical and pre-clinical development along with dormant, inactive and abandoned drugs agents. 

The HPV 16+ Cancer Pipeline report provides a holistic picture of the ongoing clinical trials, partnerships and recent happenings in the domain and growth prospects across the HPV 16+ Cancer space.

Some of the key highlights from the HPV 16+ Cancer Pipeline report:

  • The HPV 16+ Cancer Pipeline report offers a rich analysis of 14+ key players and 14+ key therapies.
  • HPV 16+ Cancer pipeline comprises emerging therapies in different stages of the clinical phase such as include VGX-3100, ISA101b, PDS0101, VB10.16, BNT113, ADXS11–001, CUE 101, HB-201, HB-202, PRGN-2009, TG 4001, KITE-439, and others. 
  • Some of the key companies working to strengthen the HPV 16+ Cancer Pipeline are  PDS Biotechnology, ISA Pharmaceuticals/Regeneron Pharmaceuticals, Inovio Pharmaceuticals, BioNTech, Transgene, Advaxis, Cue Biopharma, Hookipa Biotech, Precigen, Kite Pharma, among others
  • In March 2021, Transgene announced the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT03260023).
  • In December 2020, HOOKIPA Pharma announced positive interim Phase I data on HB-201, its replicating monotherapy for the treatment of HPV16+ cancers. The results were from the initial dose-escalation cohorts of an ongoing Phase I/II clinical trial (NCT04180215) evaluating HB- 201 as therapy for patients with advanced HPV16+ metastatic cancers.

Request for Report Sample to know more about the therapies set to grab maximum patient pool @ HPV 16+ Cancer Emerging Therapies and Forecast 

Human papillomaviruses (HPVs) are a group of viruses behind the global burden of sexually transmitted infections. With over 100 types of viruses known to date, there are at least 14 that are cImmunostimulantsonsidered as high-risk cancer-causing forms leading to cervical, head and neck, vulvar, oropharyngeal, penile, anal, and other forms of cancer.

For more information on emerging drugs, visit HPV 16+ Cancer Pipeline Analysis 

HPV 16+ Cancer Pipeline Drugs Immunostimulants

DrugCompanyPhaseMoARoA
GX 188EGenexinePhase IIImmunostimulantsIntramuscular
VGX-3100Inovio PharmaceuticalsPhase IIIGene transferenceIntramuscular
ISA101bISA Pharmaceuticals/Regeneron PharmaceuticalsPhase IIImmunostimulantsSubcutaneous
PDS0101PDS BiotechnologyPhase IIImmunostimulantsSubcutaneous
BNT113BioNTechPhase IIImmunostimulantsIntravenous
VB10.16Vaccibody AS/RochePhase IIAntigen-presenting cell modulatorsIntramuscular
ADXS11–001AdvaxisPhase IIIGene transferenceIntravenous
CUE 101Cue BiopharmaPhase IInterleukin-2 replacementsIntravenous
PRGN-2009PrecigenPhase IIImmunostimulantsSubcutaneous
HB-202Hookipa BiotechPhase I/IIImmunostimulantsIntravenous
HB-201Hookipa BiotechPhase I/IIImmunostimulantsIntravenous
TG 4001TransgenePhase IIImmunostimulantsSubcutaneous
KITE-439Kite PharmaPhase IT lymphocyte replacementsNA

Request for Sample to know more @ HPV 16+ Cancer Pipeline Analysis, Key Companies, and Futuristic Trends 

HPV 16+ Cancer Therapeutic Assessment 

The HPV 16+ Cancer Pipeline report lays down complete insights into active HPV 16+ Cancer pipeline therapies segmented by Stage, Product Type, Route of Administration, Type of Molecule, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration
Loading...
Loading...

By Molecule Type 

  • Monoclonal Antibody
  • Peptides
  • Vaccines
  • Small molecule

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Topical

By Mechanism of Action

  • Gene transference
  • Interleukin-2 replacements
  • Immunostimulants
  • Antigen-presenting cell modulators
  • T lymphocyte replacements

By Targets

  • Antigen-presenting cell
  • HPV16 protein

Discover more about recent healthcare trends and pipeline activities for Informative Business Decisions, Licensing Services  and Consulting Solutions 

Scope of the Report

Coverage: Global
Key Players: PDS Biotechnology Corp. /Merck, ISA Pharmaceuticals/Regeneron Pharmaceuticals, Inovio Pharmaceuticals, Transgene, Advaxis, Cue Biopharma, Hookipa Biotech, Precigen, Transgene, Kite Pharma, and others. 
Key HPV 16+ Cancer Pipeline Therapies: VGX-3100, ISA101b, PDS0101, VB10.16, BNT113, ADXS11–001, CUE 101, TG 4001, KITE-439, HB-201, HB-202, PRGN-2009, and others. 

Reach out @ HPV 16+ Cancer Pipeline: Novel therapies and Emerging technologies 

Table of Contents 

1Report Introduction
2HPV 16+ Cancer Disease Overview
3HPV 16+ Cancer Pipeline Outlook
4Comparative Analysis
5HPV 16+ Cancer Therapeutic Products in Clinical Stage
6HPV 16+ Cancer Therapeutic Products in Non-clinical Stage
7HPV 16+ Cancer Therapeutics Pipeline Analysis
8Inactive HPV 16+ Cancer Pipeline Products 
9Appendix
10 Report Methodology
11Consulting Services
12Disclaimer
13About DelveInsight

Visit to know more of what's covered @ HPV 16+ Cancer Emerging Therapies, Treatments and Ongoing Clinical Trials 

Related Reports

Acute Bacterial Skin And Skin Structure Infections Market
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections - Market Insights, Epidemiology, and Market Forecast-2030" report.

 Adeno Associated Virus Vectors In Gene Therapy Market
DelveInsight's "Adeno-Associated Virus Vectors in Gene Therapy - Market Insights, Epidemiology, and Market Forecast-2030" report.

Human Immunodeficiency Virus Type 1 Market
DelveInsight's "Human Immunodeficiency Virus Type-1 (HIV-1)- Market Insights, Epidemiology, and Market Forecast-2030" report. 
Bacterial Meningitis Market
DelveInsight's "Bacterial Meningitis Market Insights, Epidemiology, and Market Forecast-2030" report.

Browse through blog posts

Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market
COVID-19 Vaccine Landscape

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com


Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Loading...
Loading...
Posted In: Health CareAnalyst RatingsPress ReleasesAnalyst RecommendationsLicensing
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...